Skip to main content

Jubilant Pharmova Ltd

STALWARTMEDIUM
HealthcareBSE: 530019NSE: JUBLPHARMA
Final Score
25/100
Geometric mean of 5 dimension scores
ClassificationAG4
STRONG AVOID
Overall Rank
#145
Sector Rank
#16
Healthcare

Investment Thesis

Jubilant Pharmova presents a classic 'Stalwart Trap' where deteriorating fundamentals—specifically shrinking revenue and collapsing ROE—are masked by a high P/E valuation that assumes stability it no longer possesses. The Risk Analyst's warning regarding potential interest capitalization creates a severe governance and accounting red flag that invalidates the reported profitability metrics, while the Governance Analyst confirms promoter divestment signals a lack of insider confidence. Despite low headline debt, the combination of negative owner earnings, liquidity stress (Current Ratio < 1), and questionable accounting practices makes this a high-risk value trap rather than a compounder.

3 catalysts3 risksConviction: MEDIUMHorizon: 1y
— AG4 synthesis: This is a high-conviction 'Avoid' because all four gates fail: Fundamentals are deteriorating (Buffett/Graham scores < 30), Governance has red flags (promoter exit + accounting suspicion), Risk is elevated (potential hidden leverage), and Valuation is unjustified (28x P/E for -1% profit growth). The convergence of a 'Stalwart' label with actual 'Value Trap' characteristics creates a clear thesis against investment.
Price-to-Earnings Ratioi
28.7×
≈ sector 26.4×
Return on Capital Employedi
9.5%
▼ vs sector 14%
Return on Equityi
9.6%
▼ vs sector 12.7%
Piotroski F-Scorei
—
Market Capitalizationi
₹13.2K Cr
▲ vs sector ₹305 Cr
Dividend Yieldi
0.6%
▲ vs sector 0%

Catalysts

  • +Debt-to-Equity is manageable at 0.44, and interest coverage is healthy at 4.9x.
  • +Working Capital cycle improved drastically from 43 days to 16.3 days, improving operational efficiency.
  • +Revenue grew in 8 of the last 10 years, showing some historical resilience despite recent contraction.

Risks

  • −Stalwart Trap: Capital Erosion and Growth Stagnation — 5-year sales growth of only 3.90% combined with a 3-year ROE of just 1.41% indicates the company is failing to generate value from its equity base, characteristic of a 'slow grower' masquerading as a stalwart.
  • −Accounting Quality: Potential Interest Capitalization — Screener signals explicitly flag that the company might be capitalizing interest costs; if true, this artificially inflates Net Profit (836 Cr) and understates leverage/interest burden, making the 4.9x coverage ratio misleading.
  • −Tail risk: If the company's interest capitalization is reversed by auditors or regulators, reported profits could drop significantly, turning the 'low D/E' into a hidden crisis while the stagnant revenue prevents price hikes to cover real costs, leading to a valuation re-rating similar to a turnaround failure.

Key Items to Monitor

  • →Auditor comments on the treatment of interest costs and potential restatements.
  • →Quarterly revenue trends to confirm if contraction is cyclical or structural.
  • →Further changes in promoter holding post-divestment.
  • →Free Cash Flow vs. Net Profit divergence widening.

Detail